Kaldal, Anete
Tonstad, Serena
Jortveit, Jarle
Article History
Received: 4 October 2022
Accepted: 19 April 2023
First Online: 28 April 2023
Declarations
:
: The study was approved by Regional Committee for Medical and Health Research Ethics (REK, 2.2007.248). All study participants have signed a written informed consent form. The data collection, storage and processing were approved by Norwegian Social Science Data Services (NSD, 2007/17221). The study is registered in ClinicalTrials.gov (16.05.2008, NCT00679237). All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: AK declares no conflicts of interest.ST has received speaking fees from Pfizer.JJ has received speaking fees from Amgen, AstraZeneca, BMS, Boehringer Ingelheim, Novartis, Pfizer, and Sanofi.